Loading people...
Helen Kim is the Senior Managing Director and Chief Investment Officer at Vida Ventures in Los Angeles. She oversees life sciences venture capital investments and helped raise 825 million dollars for the firm's third fund, contributing to its two billion dollars in total assets under management. Prior to joining Vida Ventures in 2019, Kim served as a Partner at The Column Group and Executive Vice President of Business Development at Kite Pharma. At Kite Pharma, she facilitated the company's acquisition by Gilead Sciences for nearly twelve billion dollars. Her earlier career includes serving as the Chief Executive Officer of Kosan Biosciences, which was acquired by Bristol-Myers Squibb, alongside earning degrees from Northwestern University and the University of Chicago. Kim currently focuses on funding early-stage biomedical innovations and guiding biotechnology companies through major strategic partnerships.
Helen Kim stands as a distinguished Managing Director at Vida Ventures, a premier life sciences venture capital firm renowned for its commitment to funding groundbreaking scientific advancements. In her pivotal role, Helen is instrumental in shaping the firm's investment strategy, identifying high-potential opportunities, and guiding portfolio companies towards significant milestones and market success. Her work at Vida Ventures is deeply rooted in a passion for translating cutting-edge research into tangible solutions that address critical health challenges globally.
At Vida Ventures, Helen's responsibilities encompass the entire investment lifecycle. She leads rigorous due diligence processes, evaluating complex scientific data, market potential, and management teams of prospective investments. Beyond deal sourcing and execution, she actively engages with portfolio companies, providing strategic oversight, operational guidance, and leveraging her extensive network to foster growth and accelerate development. Her leadership ensures that Vida Ventures continues to back companies poised to make a profound impact on patient care.
Helen's investment focus areas are squarely within the dynamic and rapidly evolving life sciences sector. She specializes in biotechnology, particularly novel therapeutics, gene therapies, and cell therapies that promise to revolutionize disease treatment. Her expertise also extends to pharmaceuticals, where she seeks out innovative drug discovery platforms and development programs. Furthermore, Helen is keenly interested in broader healthcare innovation, including advanced medical devices, diagnostics, and digital health solutions that enhance patient outcomes and healthcare delivery. She consistently targets companies that demonstrate exceptional scientific rigor, address significant unmet medical needs, and possess the potential for transformative market disruption.
Before joining Vida Ventures, Helen Kim cultivated a distinguished career that seamlessly blends scientific acumen with robust financial expertise. She previously held key leadership positions at a prominent biopharmaceutical company, where she was instrumental in corporate development, strategic partnerships, and M&A activities. Her earlier experience also includes a tenure at another leading healthcare-focused venture capital firm, where she developed a keen eye for identifying disruptive technologies and promising early-stage ventures. Helen holds an MD from a top-tier medical institution and an MBA from a prestigious business school, providing her with a unique perspective that combines deep scientific understanding with strong business acumen.
While specific individual investments are often confidential, Helen Kim has been a driving force behind many of Vida Ventures' successful partnerships. She actively works with portfolio companies, providing strategic guidance, operational support, and leveraging her extensive network to accelerate their growth and market penetration. Her contributions have been vital in backing companies that are developing next-generation therapies for oncology, rare diseases, neurological disorders, and other critical areas of unmet medical need, aligning with Vida Ventures' mission to transform patient care through scientific innovation. Helen's dedication to fostering innovation and her strategic vision continue to solidify Vida Ventures' position as a leader in life sciences investment.
Helen Kim is a Managing Director at Vida Ventures, a leading life sciences venture capital firm. She is known for her expertise in identifying and nurturing groundbreaking investments in biotechnology, pharmaceuticals, and healthcare innovation.
Helen Kim primarily invests in the life sciences sector, focusing on biotechnology (novel therapeutics, gene/cell therapies), pharmaceuticals (drug discovery and development), and broader healthcare innovation (medical devices, diagnostics, digital health). She targets companies with transformative science addressing unmet medical needs.
Helen Kim works as a Managing Director at Vida Ventures, a prominent venture capital firm dedicated to investing in and supporting innovative life sciences companies.
